IRIS
GROSSI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.575
AS - Asia 523
NA - Nord America 277
SA - Sud America 44
AF - Africa 11
OC - Oceania 1
Totale 4.431
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 3.481
US - Stati Uniti d'America 268
SG - Singapore 215
CN - Cina 135
VN - Vietnam 117
FR - Francia 39
BR - Brasile 28
HK - Hong Kong 22
DE - Germania 15
GB - Regno Unito 11
FI - Finlandia 7
JP - Giappone 6
AR - Argentina 4
IN - India 4
MX - Messico 4
PH - Filippine 4
UA - Ucraina 4
ID - Indonesia 3
PL - Polonia 3
PY - Paraguay 3
SA - Arabia Saudita 3
TR - Turchia 3
TW - Taiwan 3
VE - Venezuela 3
BD - Bangladesh 2
CH - Svizzera 2
CO - Colombia 2
DZ - Algeria 2
EC - Ecuador 2
KE - Kenya 2
MY - Malesia 2
RS - Serbia 2
SE - Svezia 2
SV - El Salvador 2
AL - Albania 1
AU - Australia 1
BE - Belgio 1
CA - Canada 1
CV - Capo Verde 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
HN - Honduras 1
IE - Irlanda 1
IQ - Iraq 1
JM - Giamaica 1
KG - Kirghizistan 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
NL - Olanda 1
PE - Perù 1
PK - Pakistan 1
RE - Reunion 1
RO - Romania 1
RU - Federazione Russa 1
SI - Slovenia 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 4.431
Salva come PNG Salva come JPEG
Città #
Genova 1.476
Genoa 1.189
Rapallo 451
Vado Ligure 335
Singapore 99
San Jose 77
Ashburn 59
Ho Chi Minh City 36
Lauterbourg 33
Hanoi 25
Hong Kong 21
St Louis 20
Beijing 18
Frankfurt am Main 13
New York 12
Bordighera 10
Council Bluffs 10
Santa Clara 8
Helsinki 6
Los Angeles 6
São Paulo 6
City of London 5
Tokyo 5
Da Nang 4
Biên Hòa 3
Chicago 3
Haiphong 3
Hải Dương 3
Kyiv 3
Mexico City 3
Milan 3
Orem 3
Paris 3
Warsaw 3
Asunción 2
Bari 2
Belgrade 2
Buffalo 2
Bình Dương 2
Cardiff 2
Davao City 2
Istanbul 2
Jeddah 2
Marseille 2
Nairobi 2
Naples 2
Ninh Bình 2
Phủ Lý 2
San Salvador 2
Stockholm 2
Taipei 2
Thái Nguyên 2
Vinh 2
Zurich 2
Abha 1
Addis Ababa 1
Allendale 1
Americana 1
Amsterdam 1
Ancona 1
Aracaju 1
Atlanta 1
Bacoor 1
Baghdad 1
Batna City 1
Bauru 1
Bengaluru 1
Birmingham 1
Bishkek 1
Bologna 1
Braço do Norte 1
Brisbane 1
Brussels 1
Bucharest 1
Can Tho 1
Chengdu 1
Chennai 1
Chula Vista 1
Cleveland 1
Columbus 1
Cuiabá 1
Cumaná 1
Dasmariñas 1
Dublin 1
Gaziantep 1
Guarapari 1
Guaraí 1
Guayaquil 1
Guaíba 1
Hefei 1
Houston 1
Hưng Yên 1
Jaguaquara 1
Jakarta 1
Jiaxing 1
Johannesburg 1
Juiz de Fora 1
Kansas City 1
Kaohsiung 1
Kingston 1
Totale 4.040
Salva come PNG Salva come JPEG
Nome #
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 172
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 172
Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely 167
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 148
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab 145
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 141
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? 133
Liquid biopsy in non-small cell lung cancer: Highlights and challenges 132
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 129
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 128
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 128
Afatinib for the treatment of non-small cell lung cancer 126
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients 125
Exosomes: a new horizon in lung cancer 124
Gefitinib treatment outcome after progression on erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) 121
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 118
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 115
Difference in skin toxicity incidence between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC) 113
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 113
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 112
Understanding the checkpoint blockade in lung cancer immunotherapy 109
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 108
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 103
Disease stabilization as a surrogate end point in advanced non small cell lung cancer patients treated with erlotinib or gefitinib 102
Vinflunine for the treatment of non-small cell lung cancer 101
Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers 100
Hematopoietic growth factors in lung cancer 100
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 95
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 94
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 89
Skin toxicities difference between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC) 86
PCSK9 is a promising prognostic marker in patients with advanced NSCLC 84
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 82
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 82
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects 79
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 70
Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer 69
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: Can we use enemy territory at our advantage? 64
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 64
Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy” 62
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial 60
Looking for results in non-small-cell lung cancer: Is bio-chemotherapy the right answer? 44
PCSK9 as a new player in cancer: New opportunity or red herring? 13
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 11
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study 6
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 6
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 6
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial 4
Totale 4.555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.144
article - articoli 17.573
book - libri 0
conference - conferenze 1.571
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.288
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021110 0 0 0 0 0 0 0 0 0 63 18 29
2021/2022482 60 16 5 22 30 51 10 103 26 60 24 75
2022/2023514 42 34 9 51 85 94 0 43 78 6 67 5
2023/2024256 7 29 7 41 20 47 20 19 12 14 2 38
2024/2025877 22 52 30 53 121 92 101 185 30 48 67 76
2025/20261.323 192 30 82 84 221 111 233 54 140 176 0 0
Totale 4.555